Oncology · NSCLCTrial Updateclinicalmid-term

Calderasib and Pembrolizumab Study in KRAS G12C NSCLC Shows Promising Efficacy

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/17/2026, 12:31:40 AM

Assessment confidence: 67% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The ongoing study of calderasib and pembrolizumab represents a significant advancement in the treatment landscape for KRAS G12C mutant NSCLC. Positive outcomes could reshape treatment protocols and enhance competitive positioning against existing therapies. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 14 ranked evidence items (7 high-relevance).

Strategic Assessment

The strongest clinical anchor is KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475- (ClinicalTrials.gov), sub-indication match (lung cancer); mechanism alignment (kras). In lung cancer, 4 regulatory and 3 competitive items passed relevance filtering for Merck. If the trial demonstrates significant efficacy, it could lead to increased market share for the combination therapy, impacting revenue streams and competitive dynamics in the NSCLC market.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC (Humanexa Signals) — sub-indication match (lung cancer); mechanism alignment (kras). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. If successful, this combination could enhance competitive positioning against existing therapies for NSCLC, particularly in patients with high PD-L1 expression.

Regulatory Outlook

Regulatory risk is concentrated around Oncology (Cancer)/Hematologic Malignancies Approval Notifications (FDA). Entity match (oncology); Regulatory pathway relevance (approval). Successful trial results may influence regulatory approvals and treatment guidelines, particularly for patients with specific genetic markers like KRAS G12C and high PD-L1 expression.

Key Risks

Elevated medium regulatory exposure for Merck could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Merck through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

If the trial demonstrates significant efficacy, it could lead to increased market share for the combination therapy, impacting revenue streams and competitive dynamics in the NSCLC market.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for Merck may improve if Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Merck may improve if A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Program (ClinicalTrials.gov) delivers favorable follow-through.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor results for progression-free survival and overall survival outcomes as they will influence treatment protocols.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAlow relevance
Sponsor/company relevance (Merck)
FDA document
View source

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
FDA document
View source
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Program
ClinicalTrials.govmedium relevance
Mechanism alignment (PD-L1); Sponsor/company relevance (Merck)
FDA document
View source
Efficacy and Tolerance of THC 25: CBD 25 in Patients With Severe Pruritus: Multicenter, Double-blind, Randomized, Placebo-controlled Study
ClinicalTrials.govlow relevance
Sponsor/company relevance (Merck)
FDA document
View source
Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
ClinicalTrials.govlow relevance
Sponsor/company relevance (Merck)
FDA document
View source
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.govlow relevance
Sponsor/company relevance (Merck)
FDA document
View source

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (oncology)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Entity match (merck); Patient population match (first line)
FDA document
View source
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Mercklow relevance
Entity match (merck)
FDA document
View source

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (PD-L1)
FDA document
View source
CXCL13-expressing CD4(+) T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Efficacy and tolerability of linezolid as an adjunctive treatment for nontuberculous mycobacterial infections in patients with adult-onset immunodeficiency syndrome: a prospective cohort study.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
The diameter of malformation capillaries does not influence the efficacy of photodynamic therapy for facial port-wine stains: a pilot study.
PubMedlow relevance
Sponsor/company relevance (Merck)
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedlow relevance
Sponsor/company relevance (Merck)
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedlow relevance
Sponsor/company relevance (Merck)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Merck
Calderasib
Non-small Cell Lung Cancer
Oncology

Commercial impact

high

If the trial demonstrates significant efficacy, it could lead to increased market share for the combination therapy, impacting revenue streams and competitive dynamics in the NSCLC market.

Regulatory impact

medium

Successful trial results may influence regulatory approvals and treatment guidelines, particularly for patients with specific genetic markers like KRAS G12C and high PD-L1 expression.

What to watch

Monitor results for progression-free survival and overall survival outcomes as they will influence treatment protocols.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.